A Phase II, Randomized, Open-Label, Multicenter, Study Evaluating the Efficacy of Sorafenib Alone and Sorafenib in Combination With Low Dose Interferon Alpha-2a as Second-Line Treatment of Sunitinib Failure in Patients With Metastatic Renal Cell Carcinoma.

Trial Profile

A Phase II, Randomized, Open-Label, Multicenter, Study Evaluating the Efficacy of Sorafenib Alone and Sorafenib in Combination With Low Dose Interferon Alpha-2a as Second-Line Treatment of Sunitinib Failure in Patients With Metastatic Renal Cell Carcinoma.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 05 Sep 2014

At a glance

  • Drugs Sorafenib (Primary) ; Interferon alpha-2a
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Acronyms CONCERT
  • Sponsors Bayer; Bayer HealthCare
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 24 Mar 2012 This trial is recruiting in Spain and France.
    • 10 Sep 2010 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top